NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.19 by $0.12. The biotechnology company had revenue of $271.70 million for the quarter, compared to analysts' expectations of $228.17 million. Exelixis had a return on equity of 25.55% and a net margin of 64.05%. The business's revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 EPS. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Exelixis.

8 Wall Street analysts have issued 12 month target prices for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they anticipate Exelixis' stock price to reach $25.88 in the next year. This suggests a possible upside of 46.9% from the stock's current price. View Analyst Price Targets for Exelixis.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Media headlines about EXEL stock have trended negative on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Exelixis earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Exelixis.

Exelixis saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 15,690,000 shares, a decline of 5.0% from the October 31st total of 16,520,000 shares. Based on an average daily volume of 2,790,000 shares, the short-interest ratio is currently 5.6 days. Currently, 5.3% of the company's stock are sold short. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), Celgene (CELG) and Corbus Pharmaceuticals (CRBP).

Exelixis' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (3.44%), First Trust Advisors LP (1.32%), Pictet Asset Management Ltd. (1.00%), Stephens Investment Management Group LLC (0.29%), Chicago Capital LLC (0.26%) and Rhumbline Advisers (0.25%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Millennium Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Great West Life Assurance Co. Can, Capital Management Corp VA, Stifel Financial Corp and Tower Research Capital LLC TRC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

EXEL stock was purchased by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Great Point Partners LLC, State Street Corp, Man Group plc, State of New Jersey Common Pension Fund D, Mackay Shields LLC, California Public Employees Retirement System and Squarepoint Ops LLC. View Insider Buying and Selling for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $17.61.

Exelixis has a market capitalization of $5.35 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

The official website for Exelixis is http://www.exelixis.com/.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]